Do you lose more weight on 2.4mg Wegovy than on lower doses?

The misconception: reaching 2.4mg is when Wegovy 'starts working'

One of the most common things people get wrong about Wegovy is assuming the lower doses are just waiting rooms. They are not. Semaglutide is active at every step of the schedule. Most people notice reduced appetite and some early weight movement well before they reach 2.4mg, including at the very first 0.25mg starting dose. The titration exists for tolerability (nausea and other gastrointestinal effects are more likely if you jump straight to a higher dose) not because the medicine is switched off below 2.4mg.

That said, the clinical evidence does show a clear dose-response pattern. Larger doses of semaglutide generally produce greater appetite suppression. So while you may be losing weight at 1.0mg or 1.7mg, many people find the rate increases again when they move to the full maintenance dose. Whether that increase is modest or significant varies from person to person. Some find the step from 1.7mg to 2.4mg relatively minor; for others it marks a meaningful shift. If you want to understand what people typically experience at the 1.7mg level specifically, our page on 1.7mg Wegovy goes into that in more detail.

The word 'more' in the question also matters. More than what? More than 1.7mg? More than 1.0mg? Compared with 0.25mg, the difference over a full year of treatment is substantial. Compared with 1.7mg, the gap is narrower. Both are true, and neither is the full story.

What the trial data says, and what it does not say about your specific result

The STEP 1 trial is the clearest window into what 2.4mg can do. Nearly 1,961 adults without diabetes took either semaglutide 2.4mg or placebo weekly for 68 weeks. The semaglutide group lost an average of about 15% of body weight. That average conceals real variation: some participants lost considerably more, some less. A clinical average is not a personal forecast.

It is also worth knowing that STEP 1 participants followed structured dietary and physical activity guidance. The trial results reflect that combination, not semaglutide in isolation. NHS guidance on semaglutide is consistent with this: the medicine is intended to be used alongside a reduced-calorie diet and increased activity, and prescribers discuss this during clinical review.

For context on how dose relates to outcome across the full schedule, the evidence on higher Wegovy doses covers the newer 7.2mg data and where it fits. The MHRA approved the dedicated single-dose 7.2mg pen in April 2026, and trials at that dose reported around 20.7% average weight loss over 72 weeks, a result that approaches the headline figures from tirzepatide trials and represents a meaningful step up from 2.4mg for those who tolerate it.

If you are curious about what happens to weight loss if you remain at a lower dose for longer, this question about weight loss continuing at 2.4mg is addressed separately.

The honest answer about individual variation, and what it means for your treatment

We hear from people who feel let down because 2.4mg did not deliver the 15% they read about, and from others who exceeded it. Both experiences are genuine. Genetics, how long you have been living with obesity, other health conditions, medications and how closely you manage nutrition on treatment all influence the outcome. That is not a caveat designed to lower expectations; it is why clinical assessment before and during treatment matters as much as it does.

If you are trying to work out what dose you are on now and what it might mean for your results, it helps to understand how the Wegovy dose schedule is structured, not just the final number, but what each step is designed to do. And if you want to understand the broader Wegovy picture before making any decisions, our Wegovy overview covers mechanism, eligibility, costs and what the clinical review process involves.

One thing our prescribers hear fairly often: people who are considering coming off treatment because they have plateaued at a lower dose, when the right conversation is actually about whether moving up is clinically appropriate for them. That is exactly the kind of question a clinical review exists to answer. For anyone wondering whether private treatment is something they want to explore further, speaking to our prescribers is a free first step, and the consultation is reviewed the same day by a named, GPhC-registered clinician.